We are live on ! Find out more
CVS icon

CVS Health

1,654 hedge funds and large institutions have $54.6B invested in CVS Health in 2019 Q2 according to their latest regulatory filings, with 123 funds opening new positions, 754 increasing their positions, 660 reducing their positions, and 154 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more funds holding in top 10

Funds holding in top 10: 3548 (+13)

14% more repeat investments, than reductions

Existing positions increased: 754 | Existing positions reduced: 660

1% less capital invested

Capital invested by funds: $55.1B → $54.6B (-$425M)

1.44% less ownership

Funds ownership: 78.75%77.31% (-1.4%)

3% less funds holding

Funds holding: 1,7081,654 (-54)

20% less first-time investments, than exits

New positions opened: 123 | Existing positions closed: 154

20% less call options, than puts

Call options by funds: $1.14B | Put options by funds: $1.44B

Holders
1,654
Holders Change
-54
Holders Change %
-3.16%
% of All Funds
35.92%
Holding in Top 10
48
Holding in Top 10 Change
+13
Holding in Top 10 Change %
+37.14%
% of All Funds
1.04%
New
123
Increased
754
Reduced
660
Closed
154
Calls
$1.14B
Puts
$1.44B
Net Calls
-$291M
Net Calls Change
+$32.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Comerica Bank
226
Comerica Bank
Texas
$18.5M -$333K -6,184 -2%
SB
227
Suntrust Banks
Georgia
$18.3M -$595K -11,043 -3%
WPC
228
Waters Parkerson & Co
Louisiana
$18M +$3.1M +57,475 +21%
SSA
229
Schonfeld Strategic Advisors
New York
$17.9M +$2.13M +39,578 +14%
MI
230
Markston International
New York
$17.7M -$50.9K -945 -0.3%
KeyBank National Association
231
KeyBank National Association
Ohio
$17.5M -$1.04M -19,290 -6%
Truist Financial
232
Truist Financial
North Carolina
$17.4M +$2.23M +41,424 +15%
DRZID
233
DePrince Race & Zollo Inc (DRZ)
Florida
$17.2M -$266K -4,940 -2%
PTC
234
Philadelphia Trust Company
Pennsylvania
$17.1M -$1.06M -19,654 -6%
KFC
235
Klingenstein Fields & Co
New York
$17M +$377K +7,007 +2%
LTFS
236
Ladenburg Thalmann Financial Services
Florida
$16.9M +$3.32M +61,636 +25%
ERSOT
237
Employees Retirement System of Texas
Texas
$16.9M -$215K -4,000 -1%
Victory Capital Management
238
Victory Capital Management
Texas
$16.8M -$7.98M -148,276 -33%
LWCFA
239
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$16.7M -$675K -12,531 -4%
GIBU
240
Gulf International Bank (UK)
United Kingdom
$16.6M -$75.7K -1,405 -0.5%
PFU
241
Parus Finance (UK)
United Kingdom
$16.6M -$4.96M -92,100 -23%
GHA
242
GW Henssler & Associates
Georgia
$16.6M -$169K -3,145 -1%
VF
243
Vilas Fund
Illinois
$16.2M +$2.05M +38,000 +15%
Zurich Cantonal Bank
244
Zurich Cantonal Bank
Switzerland
$16M -$4.1M -76,179 -21%
ABC
245
Associated Banc-Corp
Wisconsin
$15.5M +$1.1M +20,435 +8%
Voloridge Investment Management
246
Voloridge Investment Management
Florida
$15.5M +$15.3M +284,147 New
DMIC
247
Dixon Mitchell Investment Counsel
British Columbia, Canada
$15.2M -$255K -4,727 -2%
FMII
248
Farmers & Merchants Investments Inc
Nebraska
$15.2M +$54.6K +1,014 +0.4%
FP
249
Foundry Partners
Minnesota
$15.1M -$2.41M -44,825 -14%
MG
250
Markel Group
Virginia
$15M

CVS Hedge Fund Activity: Q2 2019 in Review

1,654 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in CVS Health (CVS) for Q2 2019, worth a combined $54.6B — down 0.77% from $55.1B a quarter earlier.

Sellers outnumbered buyers: 154 funds closed out of CVS and 123 opened new positions — a net loss of 31 holders — while 660 trimmed existing stakes and 754 added.

The largest buyer was Nuveen, adding an estimated $648M. The largest seller was T. Rowe Price Associates, cutting an estimated $321M.

  • 1,654 institutional investors held CVS Health (CVS) as of Q2 2019, down from 1,708 in Q1 2019.
  • Funds reported $54.6B of CVS Health stock for Q2 2019, down 0.77% quarter-over-quarter.
  • 123 funds opened new CVS Health positions in Q2 2019 and 154 closed out, a net change of -31 holders.
  • The largest CVS Health buyer in Q2 2019 was Nuveen, an estimated $648M added.
  • The largest CVS Health seller in Q2 2019 was T. Rowe Price Associates, an estimated $321M sold.

Based on aggregated 13F filings for Q2 2019.